Results from COG0201: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer’s Disease

Elayta (CT1812) - Cognition Therap

https://alz.confex.com/alz/2024/meetingapp.cgi/Paper/89155

Everard G.B. Vijverberg, MD, PhD1,2; Susan Catalano, PhD3; Mary E. Hamby, PhD4; Michael Grundman, MD5; Jennifer Iaci, MS6; Theresa Devins, DrPH, MS6; Anthony O Caggiano, MD, PhD6

Jun 20, 2024